General Information: (434) 654-7000 OR 1-800-633-6353
Martha Jefferson is fortunate to be adding two new, state-of-the-art Varian TrueBeam Linear Accelerators for radiation therapy treatments to its extensive array of treatment options. In April 2010, Varian Medical Systems announced the unveiling of the TrueBeam, the company’s next-generation linear accelerator platform—and the timing could not have been better, as Martha Jefferson was in the midst of developing a plan for the radiation oncology department at the new hospital.
The following Q-and-A will help explain why the new technology was developed and how it will benefit patients at the new Martha Jefferson.
Q: What is a Varian TrueBeam, and why did Varian expend so much time and effort in developing this new radiation treatment platform?
A: Varian has a long and distinguished history of developing technologically innovative treatment machines that are also safe, reliable and accurate. Until the development of the TrueBeam linear accelerator, the company had always been able to modify its current line of linear accelerators to accommodate the latest advances in technology. However, Varian eventually decided to revamp its linear accelerator platform completely, from the ground up. The company improved every aspect of the technology, from patient imaging and treatment to the internal communications and monitoring system, and added new functionality as well.
Q: Why did Martha Jefferson select Varian TrueBeam linear accelerators?
A: Martha Jefferson has a history of delivering state-of-the-art radiation therapy treatments with Varian linear accelerators. TrueBeam represents the new flagship radiation treatment platform from Varian, in terms of treatment and imaging technology, efficiency of treatments, and overall workflow.
Q: How are the new linear accelerators going to improve patient care?
A: The TrueBeams utilize technology that will simply not be available on other linear accelerators—either from Varian or other vendors. Over the projected 10-to-15-year lifecycle of the equipment, it makes sense, both technologically and economically, for Martha Jefferson to ensure that the latest treatment advances will be made available to our patients.